Correlation Between Apellis Pharmaceuticals and Blueprint Medicines

Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apellis Pharmaceuticals and Blueprint Medicines Corp, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Blueprint Medicines.

Diversification Opportunities for Apellis Pharmaceuticals and Blueprint Medicines

0.43

Correlation Coefficient

Apellis Pharmaceuticals  Blueprint Medicines

Very weak diversification

The 3 months correlation between Apellis and Blueprint is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Blueprint Medicines

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to under-perform the Blueprint Medicines. In addition to that, Apellis Pharmaceuticals is 1.4 times more volatile than Blueprint Medicines Corp. It trades about -0.01 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.05 per unit of volatility. If you would invest  5,184  in Blueprint Medicines Corp on July 22, 2024 and sell it today you would earn a total of  3,416  from holding Blueprint Medicines Corp or generate 65.9% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Apellis Pharmaceuticals  vs.  Blueprint Medicines Corp

Apellis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in November 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Blueprint Medicines Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Blueprint Medicines Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in November 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Apellis Pharmaceuticals and Blueprint Medicines

The main advantage of trading using opposite Apellis Pharmaceuticals and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.

The idea behind Apellis Pharmaceuticals and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.